Research analysts at Cantor Fitzgerald issued their FY2024 EPS estimates for shares of GH Research in a report released on ...

Cantor Fitzgerald assumed coverage on shares of GH Research (NASDAQ:GHRS – Free Report) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The firm issued an ...

Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...

GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

Cantor Fitzgerald initiated coverage of GH Research (GHRS) with an Overweight rating and $14 price target Maximize Your Portfolio with Data ...

Key Insights GH Research's significant insider ownership suggests inherent interests in company's expansion A total ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

(RTTNews) - GH Research PLC (GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, announced ...

In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 after two ...